Protocol Ledger

NCT05758896 · Phase II · COMPLETED

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Interventional Phase II clinical trial protocol NCT05758896 sponsored by Aptabio Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-27 Enrollment: 218 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05758896
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)218 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05758896
Protocol FieldVerified Registry Value
NCT IdentifierNCT05758896
Consolidated Lead SponsorAptabio Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment218 participants (ACTUAL)
Registered Start Date2023-12-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05758896
Hospital Research SiteLocationSite Profile
Keimyung University, Dongsan hospitalDaegu, South KoreaOpen Hospital Dossier ->
Chungnam National University HospitalDaejeon, South KoreaOpen Hospital Dossier ->
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->
Seoul National University Bundang HospitalSeongnam-si, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI